Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 33,088 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PLACEBO Clear all
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects

NCT02267317
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Eritoran, D5W
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 22, 2026, 2:55 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Modifying Virtual Reality Analgesia With Low-Dose Pain Medication

NCT01840774
View directory record Official record
Conditions
Virtual Reality Therapy
Interventions
Low-dose pain medication (Ketalar) and saline placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 26, 2013 · Synced Oct 22, 2026, 2:55 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis

NCT00488774
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Placebo, Golimumab 1 mg per kg, Golimumab 2 mg per kg, Golimumab 4 mg per kg
Other · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Orange, California • Roseville, California • Littleton, Colorado + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2013 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Results available

An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects

NCT03084718
View directory record Official record
Conditions
Asthma
Interventions
CHF 718 pMDI, Placebo pMDI, Beclomethasone Dipropionate (BDP)
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 75 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
134
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 22, 2026, 2:55 PM EDT
Not yet recruiting Phase 2 Interventional

GV101 for Friedreich's Ataxia (FA) Treatment

NCT07870590
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
GV101, Placebo
Drug
Lead sponsor
Graviton Bioscience Corporation
Industry
Eligibility
16 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT01244490
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Extended-release Guanfacine Hydrochloride, Atomoxetine Hydrochloride, Placebo Comparator
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
San Diego, California • Maitland, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 22, 2026, 2:55 PM EDT
Withdrawn No phase listed Observational

PRP for Rotator Cuff Tears

NCT06422390
View directory record Official record
Conditions
Rotator Cuff Tears
Interventions
Platelet - Rich Plasma
Biological
Lead sponsor
Scripps Clinic
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Results available

Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis

NCT01826201
View directory record Official record
Conditions
Psoriasis
Interventions
MOL4239, Placebo
Drug
Lead sponsor
Moleculin, LLC
Industry
Eligibility
18 Years to 72 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Miami, Florida • Fridley, Minnesota • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Phase 2 Interventional

Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)

NCT07016412
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Ensifentrine 3 mg, Glycopyrrolate 21.25 mcg, Glycopyrrolate 42.5 mcg, Placebo
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
57
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-In-Human Study of LY3985297 in Healthy Participants

NCT06395012
View directory record Official record
Conditions
Healthy
Interventions
LY3985297, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Anaheim, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 22, 2026, 2:55 PM EDT
Withdrawn Phase 2 Interventional

Study of MB07811 in Subjects With Hypercholesterolemia

NCT00879112
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
MB07811, Placebo
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
11
States / cities
San Diego, California • Jacksonville, Florida • Pembroke Pines, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2011 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Not applicable Interventional Results available

Transversus Abdominis Plane (TAP) Block for Cesarean Section

NCT01015807
View directory record Official record
Conditions
Hyperalgesia, Secondary
Interventions
Bupivacaine Placebo, Clonidine Placebo, Bupivacaine, Clonidine
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury

NCT04379011
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Brivaracetam, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Englewood, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Results available

Nesiritide Therapy to Preserve Function of the Left Ventricle After Myocardial Infarction

NCT00573144
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Nesiritide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
2
States / cities
Jacksonvilee, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Not applicable Interventional Results available

Efficacy Study of Strattera for Treating Attention Disorders in Traumatic Brain Injury (TBI)

NCT00702364
View directory record Official record
Conditions
Traumatic Brain INjury
Interventions
atomoxetine, placebo
Drug
Lead sponsor
Craig Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Oct 22, 2026, 2:55 PM EDT
Recruiting Not applicable Interventional

Wild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure

NCT06735599
View directory record Official record
Conditions
Hypertension (Without Type 2 Diabetes Mellitus), High Blood Pressure, Male, Female, Adult, Cognition, Endothelial Function (Reactive Hyperemia), Oxidative Stress, Diet, Overweight, Body Composition Measurement, Gut Microbiome, Arterial Stiffness, Caucasian Whites, Inflammation, Microvascular Function
Interventions
Wild Blueberry, Placebo
Dietary Supplement
Lead sponsor
Georgia State University
Other
Eligibility
45 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Early Phase 1 Interventional Results available

Non-Opioid Pramipexole and Pain

NCT03842709
View directory record Official record
Conditions
Chronic Pain
Interventions
Pramipexole Oral Tablet, Placebo
Drug · Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of a Whole Cell Algae Fermentate on Gut Health and Overall Immune Function in Healthy Adults With Mild Gastrointestinal Issues

NCT04735809
View directory record Official record
Conditions
Healthy, Gastrointestinal Dysfunction, Cold Symptom, Flu Symptom
Interventions
Whole Cell Algae Fermentate, Placebo
Dietary Supplement
Lead sponsor
Kemin Foods LC
Industry
Eligibility
21 Years to 60 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Phase 2 Interventional

Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication

NCT00101998
View directory record Official record
Conditions
Constipation, Bowel Dysfunction
Interventions
alvimopan, placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
69
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Duarte, California + 58 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Phase 2 Interventional

SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

NCT05307328
View directory record Official record
Conditions
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
Interventions
SPI-62, Placebo
Drug
Lead sponsor
Sparrow Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Phoenix, Arizona • Fort Myers, Florida • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 22, 2026, 2:55 PM EDT
Terminated Phase 4 Interventional Results available

Mothers' Own Milk Optimization for Preterm Infants Project (MoMO PIP) Pilot Study

NCT04629534
View directory record Official record
Conditions
Vitamin D Deficiency, Nutritional Deficiency
Interventions
High dose Cholecalciferol, Cholecalciferol
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
0 Days to 45 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 22, 2026, 2:55 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of VYD2311 for the Prevention of COVID-19

NCT07298434
View directory record Official record
Conditions
COVID-19
Interventions
VYD2311-SD, VYD2311-MD, Placebo
Drug
Lead sponsor
Invivyd, Inc.
Industry
Eligibility
12 Years to 100 Years
Enrollment
1,770 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
20
States / cities
Long Beach, California • San Diego, California • Orlando, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Not applicable Interventional

Vitamin D for Muscle Metabolic Function in Cancer Cachexia

NCT03144128
View directory record Official record
Conditions
Cancer Cachexia, Vitamin D Deficiency
Interventions
Vitamin D, Placebo
Dietary Supplement
Lead sponsor
David Travis Thomas
Other
Eligibility
45 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 22, 2026, 2:55 PM EDT
Completed Phase 1 Interventional

A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI)

NCT04891965
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
ART24, Placebo
Biological · Drug
Lead sponsor
Adiso Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Palm Springs, California • Clearwater, Florida • Doral, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 22, 2026, 2:55 PM EDT